PEI’s Neurodyn Buys NeuroQuest
Neurodyn, the P.E.I. biotech developing early treatments for neurological diseases, has closed a deal to buy NeuroQuest, the Halifax-based drug development company spun out of Origin Biomed two years ago.
This interprovincial deal is significant because it enlarges one of the region’s leading young biotech companies, marries two superb management teams and combines their suite of drug candidates that target neurological afflictions.
Founded by CEO Kenneth Cawkell, University of British Columbia scientist Chris Shaw and CSO Denis Kay, Neurodyn has discovered a natural extract from